Best Vascular, a TeamBest Global Company, Celebrates 18 Year Anniversary of Serving the Cardiology Community
Washington, DC, USA – April 5, 2024
Best Vascular/Novoste celebrates its 18th anniversary since Best Vascular acquired Novoste on March 9th 2006. Dr. Krishnan Suthanthiran and Best Medical International (BMI), one of the TeamBest Global Companies, has been in Vascular Brachytherapy (VBT) for over 30 years. Starting in 1992, BMI engaged in pre-clinical research in animals with Dr. Ron Waksman of Washington Hospital Center in Washington, D.C. (at Emory University until 1997), and Dr. Ian Crocker at Emory University in Atlanta, Georgia and also starting in 1994, carried out Phase I Human Clinical Trials with Dr. Paul Teirstein, Dr. Vince Mazzoula, and Dr. Shiresh Jani of Scripps Clinic, La Jolla, California.
Novoste was established in 1995 and became a public company soon thereafter. In January 1996, at the very first Vascular Brachytherapy Conference in Atlanta, Georgia, with encouragement from Dr. Ron Waksman and Dr. Ian Crocker, BMI tried to work with Novoste and again in early 2004, but had little success in working with the Novoste management in place at that time.
Novoste assets were purchased by BMI in March 2006 as Novoste was planning to close down the Vascular Therapy operation.
VBT was approved for clinical use by US FDA on November 3, 2000. BMI continues to support and expand the use of VBT and is currently involved in developing new technologies.
Now, Best Vascular/Novoste — the only company to continue to support and promote Vascular Brachytherapy — is expanding in the coming years with new technologies and clinical trials.
Best Vascular/Novoste is eternally grateful to Dr. Ron Waksman, Dr. Paul Tierstein, Dr. Ian Crocker, Dr. Vince Mazzoula, and Dr. Shiresh Jani for the inventions and promotion of Vascular Brachyyherapy.
Best Vascular/Novoste will be exhibiting at American College of Cardiology conference in Atlanta, GA from April 6-8, 2024. Please visit us at booths 3005, 3104 and 3107.
In addition to VBT products, BMI will be exhibiting self-shielded Cyclotron for producing a range of radioisotopes for cardiology, neurology, and oncology applications, as well as state-of-the-art high-resolution ultrasound for cardiology applications.